{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ocular+Pain",
    "query": {
      "condition": "Ocular Pain"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 148,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ocular+Pain&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T01:50:38.691Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02630719",
      "title": "Timolol Eye Drops in the Treatment of Acute Migraine Headache",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Timolol eye drops",
          "type": "DRUG"
        },
        {
          "name": "Artificial tears",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Missouri, Kansas City",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2016-01",
      "completion_date": "2017-08-01",
      "has_results": true,
      "last_update_posted_date": "2019-05-15",
      "last_synced_at": "2026-05-22T01:50:38.691Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02630719"
    },
    {
      "nct_id": "NCT02508337",
      "title": "Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Inflammation",
        "Pain",
        "Cataract"
      ],
      "interventions": [
        {
          "name": "XG-102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xigen SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 309,
      "start_date": "2015-07",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2017-01-24",
      "last_synced_at": "2026-05-22T01:50:38.691Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02508337"
    },
    {
      "nct_id": "NCT02786901",
      "title": "LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract",
        "Pain",
        "Ocular Inflammation"
      ],
      "interventions": [
        {
          "name": "Loteprednol Etabonate Ophthalmic Gel dosed TID",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol Etabonate Ophthalmic Gel dosed BID",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2016-06",
      "completion_date": "2017-07-01",
      "has_results": true,
      "last_update_posted_date": "2021-01-08",
      "last_synced_at": "2026-05-22T01:50:38.691Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Quincy",
          "state": "Massachusetts"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02786901"
    },
    {
      "nct_id": "NCT02235272",
      "title": "Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Inflammation",
        "Pain",
        "Cataract"
      ],
      "interventions": [
        {
          "name": "XG-102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xigen SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 339,
      "start_date": "2014-09",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-24",
      "last_synced_at": "2026-05-22T01:50:38.691Z",
      "location_count": 1,
      "location_summary": "Garden Grove, California",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02235272"
    },
    {
      "nct_id": "NCT07434635",
      "title": "APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Eye Disorders"
      ],
      "interventions": [
        {
          "name": "Atropine 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2026-02",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-05-22T01:50:38.691Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07434635"
    },
    {
      "nct_id": "NCT06964269",
      "title": "Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Autoimmune Diseases",
        "Dry Eye",
        "Neurotrophic Keratitis"
      ],
      "interventions": [
        {
          "name": "Acthar Gel 80 UNT/ML Injectable Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Toyos Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-02-11",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-05-11",
      "last_synced_at": "2026-05-22T01:50:38.691Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06964269"
    },
    {
      "nct_id": "NCT04975971",
      "title": "A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Anterior Chamber Inflammation",
        "Ocular Pain",
        "Corneal Edema",
        "Corneal Defect",
        "Penetrating KeratoPlasty",
        "Nuclear Cataract",
        "Cortical Cataract",
        "Cataract Senile"
      ],
      "interventions": [
        {
          "name": "Dextenza 0.4Mg Ophthalmic Insert",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nicole Fram M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-03-09",
      "completion_date": "2021-05-19",
      "has_results": false,
      "last_update_posted_date": "2021-07-26",
      "last_synced_at": "2026-05-22T01:50:38.691Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04975971"
    },
    {
      "nct_id": "NCT00198484",
      "title": "Evaluation of Vitrase as a Spreading Agent",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Vitrase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2004-10",
      "completion_date": "2005-02",
      "has_results": false,
      "last_update_posted_date": "2013-03-14",
      "last_synced_at": "2026-05-22T01:50:38.691Z",
      "location_count": 18,
      "location_summary": "Newport Beach, California • Sacramento, California • Littleton, Colorado + 15 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Oglethorpe",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00198484"
    },
    {
      "nct_id": "NCT04130802",
      "title": "OCS-01 in Treating Inflammation and Pain in Post-cataract Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Inflammation Corneal",
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oculis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2019-09-27",
      "completion_date": "2020-01-31",
      "has_results": true,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-05-22T01:50:38.691Z",
      "location_count": 4,
      "location_summary": "Petaluma, California • Roseburg, Oregon • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Roseburg",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04130802"
    },
    {
      "nct_id": "NCT06565416",
      "title": "Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Opioid Use Disorder",
        "Opioid Misuse",
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "Implementation Strategies",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2023-06-01",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-05-22T01:50:38.691Z",
      "location_count": 3,
      "location_summary": "Arcata, California • Minneapolis, Minnesota • Toppenish, Washington",
      "locations": [
        {
          "city": "Arcata",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Toppenish",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06565416"
    }
  ]
}